Zhou Zhiyong, Todd Charles W, Wohlhueter Robert M, Price April, Xiao Lihua, Schnake Paul, Bonner Phillip Cullison, Martin Amy M, Goldman Ira F, De La Vega Patricia, Udhayakumar Venkatachalam, Lal Altaf A
Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA.
Hum Vaccin. 2006 Jan-Feb;2(1):14-23. doi: 10.4161/hv.2.1.2437. Epub 2006 Jan 21.
A synthetic multistage, multi-epitope Plasmodium falciparum malaria antigen (FALVAC-1A) was designed and evaluated in silico, and then the gene was constructed and expressed in Escherichia coli. The FALVAC-1A protein was purified by inclusion body isolation, followed by affinity and ion exchange chromatography. Although FALVAC-1A was a synthetic antigen, it folded to a specific, but as yet incompletely defined, molecular conformation that was stable and comparable from lot to lot. When formulated with four different adjuvants, FALVAC-1A was highly immunogenic in rabbits, inducing not only ELISA reactivity to the cognate antigen and most of its component epitopes, but also in vitro activity against P. falciparum parasites as demonstrated by inhibition of sporozoite invasion, antibody dependent cellular inhibition and the immunofluorescence assay.
设计了一种合成的多阶段、多表位恶性疟原虫疟疾抗原(FALVAC-1A),并进行了计算机模拟评估,然后构建该基因并在大肠杆菌中表达。通过包涵体分离,随后进行亲和色谱和离子交换色谱,对FALVAC-1A蛋白进行了纯化。尽管FALVAC-1A是一种合成抗原,但它折叠成一种特定的、但尚未完全确定的分子构象,这种构象稳定且批次间具有可比性。当与四种不同佐剂配制时,FALVAC-1A在兔中具有高度免疫原性,不仅诱导对同源抗原及其大部分组成表位的ELISA反应性,还通过抑制子孢子入侵、抗体依赖性细胞抑制和免疫荧光测定证明其对恶性疟原虫寄生虫具有体外活性。